Medical Device VC Firms Directory
- Borrowed Pen
- Apr 6
- 5 min read
How to Approach Investors and What They Expect from MedTech Founders
Raising capital for a medical device company is not the same as raising capital for SaaS.
Investors in medtech evaluate:
Regulatory risk
Reimbursement pathways
Clinical validation
Capital intensity
Time to exit
Adoption barriers
They know development timelines are longer. They know capital requirements are higher. They know FDA clearance does not automatically equal revenue. So if you’re approaching venture capital firms as a medical device founder or marketer, preparation is everything. So we made this guide to walk you through:
What you need before approaching investors
How to determine which VC firms to target
What investors expect to see
A curated directory of medical device-focused venture capital firms
Why marketing strategy directly impacts fundraising success
What You Need Before Approaching Medical Device Investors
Serious medtech investors expect more than enthusiasm and a prototype. The need proof your technology has market demand, is regulatory compliant, and will by accepted into hospital and payor systems. Here is what to put together to show that you are ready to pass their due diligence:
1. A Clear One-Sheet
Your one-sheet should include:
Problem statement
Target market and clinical indication
Device classification and regulatory pathway
Competitive differentiation
Current traction or milestones
Capital ask and projected use of funds
It should be concise, credible, and data-backed.
2. A Professional Pitch Deck
Medical device pitch decks must address:
Clinical need and unmet demand
Regulatory pathway (510(k), De Novo, PMA, CE Mark, etc.)
Reimbursement strategy
Market size (TAM, SAM, SOM)
Development timeline
Clinical validation plan
Go-to-market strategy
Financial projections
Exit strategy
If regulatory and reimbursement risk are not clearly articulated, investors will hesitate.
3. Regulatory & Clinical Clarity
Investors want to know:
Is there a predicate device?
Is this Class I, II, or III?
What is the expected submission timeline?
What clinical evidence is required?
What are the regulatory risks?
Uncertainty here signals delay and capital burn.
4. Reimbursement Strategy
Especially in the U.S., investors will ask how your device's procedure will be reimbursed by insurance companies. They will ask:
Is there existing CPT or HCPCS coding?
Is this hospital capital equipment or disposable revenue?
What is the reimbursement landscape?
Are payers incentivized to adopt it?
Revenue predictability matters especially within complex medical systems.
5. Commercialization Plan
Investors expect clarity on:
Market alignment
Buyer roles (physicians, VACs, procurement, etc.)
Sales channel (direct, distributor, hybrid)
Pricing model
Early adoption targets
If your commercialization story is vague, your valuation will suffer.
How to Determine Which Investors to Approach
Not all venture capital firms invest in medical devices and even among those that do, their particular specialization matters. Here’s how to narrow your list:
1. Match Stage
Pre-seed / Seed: Look for early-stage life sciences funds
Series A: Firms that invest in clinical-stage medtech
Growth / Series B+: Funds experienced in scaling commercial medtech companies
2. Match Subspecialty
Many firms specialize in specific verticals:
Cardiovascular
Orthopedics
Digital health / SaMD
Diagnostics
Surgical robotics
Implantables
Approaching a digital health investor with a capital-intensive implantable device may not resonate.
3. Geographic Focus
Some VCs invest primarily in:
U.S.-based companies
European CE Mark-first strategies
Asia-Pacific medtech
Geographic alignment impacts regulatory planning and exit strategy.
4. Exit History
Review past portfolio exits:
IPO vs. strategic acquisition
Average hold period
Size of exits
If your device targets acquisition by a strategic buyer, look for firms with strong medtech exit networks.
What Medical Device Investors Expect to See
Medtech investors are risk-calibrated. They expect:
Strong IP protection
Clear regulatory strategy
Realistic development timelines
Credible clinical advisors
Defined reimbursement pathway
Market validation
Thoughtful capital allocation
Team experience in regulated industries
They do not expect:
Overly aggressive timelines
Ignored regulatory hurdles
Vague TAM claims
Marketing without compliance awareness
Above all, they want confidence that risk is understood and mitigated.
Medical Device Specialty VC Firms Directory
Below is a curated list of well-known venture capital firms that actively invest in medical devices and medtech innovation.
Firm Name | Website | Investment Appetite | Specialty Focus |
Accelmed Partners | Growth-stage | Global medtech, commercialization scaling | |
BlueStone Venture Partners | Early-stage | Medical devices, strong clinician-founder focus | |
Broadview Ventures | Early-stage | Cardiovascular and neurovascular devices, mission-driven | |
Catalio Capital Management | Multi-stage | Data-driven healthcare investing, including medtech | |
Deerfield Management | Multi-stage | Healthcare innovation, medtech, regulatory-heavy investments | |
Domain Associates | Early to growth | Medical devices and healthcare services | |
Elevation Capital (formerly MPM Capital MedTech) | Early-stage | Medtech and life sciences innovation | |
Epidarex Capital | Early-stage | High-impact medtech and translational science | |
Frazier Healthcare Partners | Growth to late-stage | Healthcare and medical technology, commercialization focus | |
Gilde Healthcare | Growth-stage | European medtech and healthcare services | |
HealthQuest Capital | Growth equity | Commercial-stage medtech and diagnostics | |
HLM Venture Partners | Growth-focused | Healthcare services and medical technology | |
Johnson & Johnson Innovation – JJDC | Early to growth | Broad medtech and life sciences innovation | |
KCK Group (Health Tech) | Flexible | Healthcare and medtech with operational involvement | |
Lightstone Ventures | Early-stage | Breakthrough medtech and therapeutics | |
Longitude Capital | Growth equity | Late-stage medical technology and healthcare companies | |
LSP (Life Sciences Partners) | European-focused | Medtech and life sciences | |
Medtronic Ventures | Strategic venture arm | Devices aligned with Medtronic strategic priorities | |
NEA (New Enterprise Associates) | Early to growth stage | Broad healthcare, including medical devices and life sciences | |
OrbiMed | Multi-stage | Global healthcare and medtech, strong regulatory experience | |
Perceptive Advisors | Multi-stage | Life sciences and medtech, public/private crossover | |
Questa Capital | Growth-stage | Medical devices and healthcare services | |
Sante Ventures | Early to growth | Medtech, healthcare services, and digital health | |
Shifamed | Company creation + early-stage | Medtech venture studio with deep operator expertise | |
Sofinnova Partners | Early-stage | Medical devices, biotech, European medtech | |
SV Health Investors | Early to growth | Medtech, biotech, healthcare services, transatlantic focus | |
The Vertical Group | Early-stage | Medical device innovation, capital markets advisory crossover | |
Third Rock Ventures | Early-stage | Breakthrough science, including device-enabled platforms | |
Vensana Capital | Early to growth | Pure-play medtech, commercialization-focused | |
Versant Ventures | Early to mid-stage | Healthcare and device innovation |
Note: Always confirm each firm’s current thesis and portfolio focus before outreach. Investment mandates evolve.
Why Marketing Strategy Directly Impacts Fundraising
Fundraising rarely begins in the investor meeting. Long before a pitch deck appears on a screen, investors are forming opinions based on the materials that introduce your company to the market. Your website, executive summary, thought leadership, clinical narrative, competitive positioning, and regulatory framing all shape how investors interpret the opportunity. Messaging becomes part of the evaluation process because it reflects how clearly the company understands its own market, product, and path to commercialization.
When those elements are disconnected from regulatory and market realities, investors often question operational discipline. Clear, structured marketing tells a different story. It shows that leadership understands the buyer, the clinical problem, and the regulatory environment the product must navigate. Strong medtech messaging signals market awareness, regulatory literacy, and commercial readiness.
In practical terms, it communicates your organizational maturity before the first fundraising conversation even begins.
How Borrowed Pen Supports Medical Device Fundraising
At Borrowed Pen, we specialize in medical device marketing built for regulated, complex industries. We help founders and leadership teams:
Refine pitch decks and executive summaries
Develop investor-ready messaging
Clarify regulatory positioning
Strengthen commercialization narratives
Create authority-building thought leadership
Align marketing with compliance requirements
If you’re preparing to raise capital for your medical device company, your messaging needs to reflect strategic clarity, regulatory understanding, and commercial confidence. We help you build that foundation. Learn more about our medical device marketing services.
Comments